ReviewMolecular therapy. Nucleic acids2020
Crosstalk between RNA m
Open access · goldAbstract readReview
In one paragraph
Review in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 76 citations in OpenAlex.
- The translational roles of circular RNAs in cancers and their underlying molecular mechanisms.Medical oncology (Northwood, London, England) · 2026Review
- Expanded insights into the mechanisms of RNA-binding protein regulation of circRNA generation and function in cancer biology and therapy.Genes & diseases · 2025Review
- The Role of M6A LncRNA Modification in Papillary Thyroid Cancer.International journal of molecular sciences · 2025Review
- Crosstalk Between m6A RNA Methylation and miRNA Biogenesis in Cancer: An Unholy Nexus.Molecular biotechnology · 2024Review
- Article
- CircGNAO1 strengthens its host gene GNAO1 expression for suppression of hepatocarcinogenesis.Heliyon · 2024Article
- The m6 RNA methylation regulator KIAA1429 is associated with autophagy-mediated drug resistance in lung cancer.FASEB bioAdvances · 2024Article
- Comprehensive analysis of m6A RNA methylation regulators in esophageal carcinoma.Translational cancer research · 2024Article
- The mFrontiers in endocrinology · 2024Review
- Identification of potential novel N6-methyladenosine effector-related lncRNA biomarkers for serous ovarian carcinoma: a machine learning-based exploration in the framework of 3P medicine.Frontiers in pharmacology · 2024Article
- m6A-modified circABCC4 promotes stemness and metastasis of prostate cancer by recruiting IGF2BP2 to increase stability of CCAR1.Cancer gene therapy · 2023Article
- Review
- METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.BMC gastroenterology · 2023Article
- LncRNA DGUOK-AS1 facilitates non-small cell lung cancer growth and metastasis through increasing TRPM7 stability via m6A modification.Translational oncology · 2023Article
- Macrophage membrane-coated nanovesicles for dual-targeted drug delivery to inhibit tumor and induce macrophage polarization.Bioactive materials · 2023Article
- The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer.Frontiers in oncology · 2023Review
- Identification of m6A-related lncRNAs for thyroid cancer recurrence.Gland surgery · 2023Article
- Article
- Research progress on the interaction between long non‑coding RNAs and RNA‑binding proteins to influence the reprogramming of tumor glucose metabolism (Review).Oncology reports · 2022Review
- The m6A-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Tumor Immune Infiltration in Ovarian Cancer.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Fengsheng DaiShanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China; Department of Otolaryngology Head & Neck Surgery, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China.
Yongyan WuShanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China; Shanxi Province Clinical Medical Research Center for Precision Medicine of Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, P. R. China. Electronic address: wuyongyan@sxent.org.
Yan LuDepartment of Otolaryngology Head & Neck Surgery, The First Hospital of Jinzhou Medical University, Jinzhou 121001, P. R. China.
Changming AnDepartment of Head and Neck Surgery, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, P. R. China.
Xiwang ZhengShanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China; Shanxi Province Clinical Medical Research Center for Precision Medicine of Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China.
Li DaiShanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China; Department of Otolaryngology Head & Neck Surgery, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China.
Yujia GuoShanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China; Shanxi Province Clinical Medical Research Center for Precision Medicine of Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China.
Linshi ZhangDepartment of Thyroid Surgery, Second Affiliated Hospital of Zhejiang University, Hangzhou 310009, P. R. China.
Huizheng LiDepartment of Otolaryngology Head & Neck Surgery, Dalian Municipal Friendship Hospital of Dalian Medical University, Dalian 116100, P. R. China.
Wei XuDepartment of Head & Neck Surgery, Shandong Provincial ENT Hospital Affiliated to Shandong University, Jinan 250022, P. R. China; Shandong Provincial Institute of Otolaryngology, Jinan 250022, P. R. China; Key Laboratory of Otolaryngology, Ministry of Health, Shandong University, Jinan 250022, P. R. China. Electronic address: xuwhns@126.com.
Wei GaoShanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China; Shanxi Province Clinical Medical Research Center for Precision Medicine of Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China; Department of Otolaryngology Head & Neck Surgery, First Hospital of Shanxi Medical University, Taiyuan 030001, P. R. China; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, P. R. China. Electronic address: gaoweisxent@sxent.org.
Shanxi Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNDalian Medical University · CNJinzhou Medical University · CNSecond Affiliated Hospital of Zhejiang University · CNShandong University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m
Indexed as
cancercircular RNAlong non-coding RNAmicroRNAN6-methyladenosinenon-coding RNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.